Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Opicapone

FDA-approved product (capsule, oral), marketed as Ongentys.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Opicapone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other dopaminergic agents
FDA pharmacologic class
Catechol-O-Methyltransferase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Opicapone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Opicapone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

    NCT01568047 · start 2010-02

    Registered record
    Registry ID
    NCT01568047
    Conditions
    Parkinson's Disease
    Interventions
    Placebo; BIA 9-1067; BIA 9-1067; BIA 9-1067; Levodopa/Carbidopa; Levodopa/Benzerazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionPlacebo; BIA 9-1067; BIA 9-1067; BIA 9-1067 +2 more
    PhasePhase 2
    Registry statusCompleted

  • Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

    NCT02169414 · start 2010-02

    Registered record
    Registry ID
    NCT02169414
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067 5 mg; BIA 9-1067 25 mg; levodopa/carbidopa 100/25; Placebo; levodopa/benserazide 100/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-07
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067 5 mg; BIA 9-1067 25 mg; levodopa/carbidopa 100/25; Placebo +1 more
    PhasePhase 1
    Registry statusCompleted

  • Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

    NCT01519284 · start 2009-11

    Registered record
    Registry ID
    NCT01519284
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067 5 mg; Entacapone; Placebo; levodopa/carbidopa; BIA 9-1067 15 mg; BIA 9-1067 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2011-06
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067 5 mg; Entacapone; Placebo; levodopa/carbidopa +2 more
    PhasePhase 1
    Registry statusCompleted

  • Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

    NCT01532128 · start 2009-11

    Registered record
    Registry ID
    NCT01532128
    Conditions
    Parkinson Disease
    Interventions
    rasagiline; BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    Interventionrasagiline; BIA 9-1067
    PhasePhase 1
    Registry statusCompleted

  • Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

    NCT01532141 · start 2009-11

    Registered record
    Registry ID
    NCT01532141
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Rasagiline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Rasagiline
    PhasePhase 1
    Registry statusCompleted

  • Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide

    NCT01536366 · start 2009-06

    Registered record
    Registry ID
    NCT01536366
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-01
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Repaglinide
    PhasePhase 1
    Registry statusCompleted

  • Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

    NCT02169440 · start 2009-06

    Registered record
    Registry ID
    NCT02169440
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067; Warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06
    Completion
    2009-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067; Warfarin
    PhasePhase 1
    Registry statusCompleted

  • Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites

    NCT01515891 · start 2009-05

    Registered record
    Registry ID
    NCT01515891
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-09
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

    NCT01568034 · start 2009-04

    Registered record
    Registry ID
    NCT01568034
    Conditions
    Parkinson's Disease
    Interventions
    BIA 9-1067; BIA 9-1067; BIA 9-1067; Placebo; Levodopa/Carbidopa; Levodopa/Benzerazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-02
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBIA 9-1067; BIA 9-1067; BIA 9-1067; Placebo +2 more
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa

    NCT01533077 · start 2009-03

    Registered record
    Registry ID
    NCT01533077
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Sinemet® 100/25 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Sinemet® 100/25 mg
    PhasePhase 1
    Registry statusCompleted

  • Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

    NCT01533116 · start 2009-03

    Registered record
    Registry ID
    NCT01533116
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067; Placebo; levodopa/carbidopa; levodopa/benserazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-03
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067; Placebo; levodopa/carbidopa; levodopa/benserazide
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

    NCT02169466 · start 2009-01

    Registered record
    Registry ID
    NCT02169466
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067; Placebo; Madopar® HBS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067; Placebo; Madopar® HBS
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects

    NCT02092168 · start 2008-10

    Registered record
    Registry ID
    NCT02092168
    Conditions
    Parkinson Disease
    Interventions
    BIA 9-1067
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionBIA 9-1067
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

    NCT02169453 · start 2008-10

    Registered record
    Registry ID
    NCT02169453
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067; Placebo; Sinemet® CR 100/25
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067; Placebo; Sinemet® CR 100/25
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

    NCT02169479 · start 2008-09

    Registered record
    Registry ID
    NCT02169479
    Conditions
    Parkinson's Disease (PD)
    Interventions
    BIA 9-1067; Placebo; Sinemet® 100/25
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionBIA 9-1067; Placebo; Sinemet® 100/25
    PhasePhase 1
    Registry statusCompleted